Xencor Inc (XNCR)
Xencor Inc (XNCR) from its SEC filings: 2025 revenue $125.6 million (+14% vs the year before), net margin -73%, free cash flow -$138.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $125.6 million |
| Revenue growth | +14% |
| Net income | -$91.9 million |
| Net margin | -73.2% |
| Free cash flow | -$138.3 million |
| Diluted EPS | $-1.24 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +18% |
| Cash | $44.7 million |
| Long-term debt | $77.5 million |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.